Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery - A systematic literature review

Critical Care

Volumn 9, Issue 3, 2005, Pages 266-279

  Gillies, Michael ^a   Bellomo, Rinaldo ^a   Doolan, Laurie ^b   Buxton, Brian ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMRINONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CATECHOLAMINE DERIVATIVE; CLONIDINE; DOBUTAMINE; DOPAMINE; DOPEXAMINE; ENALAPRIL; ENOXIMONE; GLYCERYL TRINITRATE; ILOPROST; INOTROPIC AGENT; LEVOSIMENDAN; LOPRINONE; MILRINONE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RANITIDINE;

BLOOD CLOTTING DISORDER; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FORWARD HEART FAILURE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART OUTPUT; HEART SURGERY; HUMAN; HYPERTENSION; ISCHEMIA; LACTIC ACIDOSIS; LUNG ARTERY PRESSURE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGIONAL PERFUSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA;

CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CATECHOLAMINES; CORONARY ARTERY BYPASS; DOBUTAMINE; HUMANS; PHOSPHODIESTERASE INHIBITORS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; VENTILATOR WEANING;

EID: 20444397741     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc3024     Document Type: Review

References (97)

1. Boldt J, Hammermann H, Hempelmann G: What is the place of the phosphodiesterase inhibitors? Eur J Anaesthiol Suppl 1993, 8:33-37.
2. Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A, European Milrinone Multicenter Trial Group: Comparison of the haemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth 2001, 15:306-315.
3. Polonen P, Ruokonen E, Hippelainen M, Poyhonen M, Takala J: A prospective, randomised study of goal-oriented haemodynamic therapy in cardiac surgical patients. Anesth Analg 2000, 90:1052-1059.
4. Cook DJ, Guyatt GH, Laupacis A, Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992, 102:305S-311S.
5. Gunnicker M, Brinkmann M, Donovan TJ, Freund U, Schieffer M, Reidemeister JC: The efficacy of amrinone or adrenaline on low cardiac output following cardiopulmonary bypass in patients with coronary artery disease undergoing preoperative bete-blockade. Thorac Cardiovasc Surg 1995, 43:153-160.
6. Royster RL, Butterworth JF 4th, Prielipp RC, Robertie PG, Kon ND, Tucker WY, Dudas LM, Zaloga GP: A randomised, blinded, placebo controlled evaluation of calcium chloride and epinephrine for inotropic support after emergence from cardiopulmonary bypass. Anesth Analg 1992, 74:3-13.
7. Linton NW, Linton RA: Haemodynamic response to a small intravenous bolus injection of epinephrine in cardiac surgical patients. Eur J Anaesthesiol 2003, 20:298-304.
8. Royster RL, Butterworth JF 4th, Prielipp RC, Zaloga GP, Lawless SG, Spray BJ, Kon ND, Wallenhaupt SL, Cordell AR: Combined inotropic effects of amrinone and epinephrine after cardiopulmonary bypass in humans. Anesth Analg 1993, 77:662-672.
9. Lobato EB, Gravenstein N, Martin TD: Milrinone, not epinephrine, improves left venticular compliance after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000, 14:374-377.
10. Butterworth JF 4th, Prielipp RC, Royster RL, Spray BJ, Kon ND, Wallenhaupt SL, Zaloga GP: Dobutamine increases heart rate more than epinephrine in patients recovering from aortocoronary bypass surgery. J Cardiothorac Vasc Anesth 1992, 6:535-541.
11. Balderman SC, Aldridge J: Pharmacologic support of the myocardium following aortocoronary bypass surgery: a comparative study. J Clin Pharmacol 1986, 26:175-183.
12. Totaro RJ, Raper RF: Epinephrine-induced lactic acidosis following cardiopulmonary bypass. Crit Care Med 1997, 25: 1693-1699.
13. Lobato EB, Urdaneta F, Martin TD, Gravenstein N: Effects of milrinone versus epinephrine on grafted internal mammary artery flow after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000, 14:9-11.
14. Cracowski JL, Chavanon O, Durand M, Borrel E, Devillier P, Mallion JM, Blin D: Effect of low-dose positive inotropic drugs on human internal mammary artery flow. Ann Thorac Surg 1997, 64:1742-1746.
15. DiNardo JA, Bert A, Schwartz MJ, Johnson RG, Thurer RL, Weintraub RM: Effects of vasoactive drugs on flows through left internal mammary artery and saphenous vein grafts in man. J Thorac Cardiovasc Surg 1991, 102:730-735.
16. Salomon NW, Plachetka JR, Copeland JG: Comparison of dopamine and dobutamine following coronary artery bypass grafting. Ann Thorac Surg 1982, 33:48-54.
17. Rosseel PM, Santman FW, Bouter H, Dott CS: Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine? Intensive Care Med 1997, 23:962-968.
18. Tarr TJ, Moore NA, Frazer RS, Shearer ES, Desmond MJ: Haemodynamic effects and comparison of enoximone, dobutamine and dopamine following mitral valve surgery. Eur J Anaesthesiol Suppl 1993, 8:15-24.
19. Davis RF, Lappas DG, Kirklin JK, Buckley MJ, Lowenstein E: Acute oliguria after cardiopulmonary bypass: renal functional improvement with low-dose dopamine infusion. Crit Care Med 1982, 10:852-856.
20. Woo EB, Tang AT, El-Gamel A, Keevil B, Greenhalgh D, Patrick M, Jones MT, Hooper TL: Dopamine therapy for patients at risk of renal dysfunction following cardiac surgery: science or fiction? Eur J Cardiothorac Surg 2002, 22:106-111.
21. Tang AT, El-Gamel A, Keevil B, Yonan N, Deiraniya AK: The effect of 'renal-dose' dopamine on renal tubular function following cardiac surgery: assessed by measuring retinol binding protein (RBP). Eur J Cardiothorac Surg 1999, 15:717-721, discussion 721-722.
22. Lema G, Urzua J, Jalil R, Canessa R, Moran S, Sacco C, Medel J, Irarrazaval M, Zalaquett R, Fajardo C, et al.: Renal protection in patients undergoing cardiopulmonary bypass with preoperative abnormal renal function. Anesth Analg 1998, 86:3-8.
23. Myles PS, Buckland MR, Schenk NJ, Cannon GB, Langley M, Davis BB, Weeks AM: Effect of 'renal-dose' dopamine on renal function following cardiac surgery. Anaesth Intensive Care 1993, 21:56-61.
24. Jakob SM, Ruokonen E, Takala J: Effects of dopamine on systemic and regional blood flow and metabolism in septic and cardiac surgery patients. Shock 2002, 18:8-13.
25. Jakob SM, Ruokonen E, Rosenberg PH,Takala J: Effect of dopamine induced changes in splanchnic blood flow on MEGX production from lidocaine in septic and cardiac surgery patients. Shock 2002, 18:1-7.
26. Thoren A, Elam M, Ricksten SE: Differential effects of dopamine, dopexamine and dobutamine on jejunal mucosal perfusion early after cardiac surgery. Crit Care Med 2000, 28: 2338-2343.
27. McNicol L, Andersen LW, Liu G, Doolan L, Baek L: Markers of splanchnic perfusion and intestinal translocation of endotoxins during cardiopulmonary bypass: effects of dopamine and milrinone. J Cardiothorac Vasc Anesth 1999, 13:292-298.
28. Gardeback M, Settergren G: Dopexamine and dopamine in the prevention of low gastric mucosal pH following cardiopulmonary by-pass. Acta Anaesthesiol Scand 1995, 39:1066-1070.
29. Schneider M, Valentine S, Hegde RM, Peacocks J, March S, Dobb GJ: The effect of different bypass flow rates and low-dose dopamine on gut mucosal perfusion and outcome in cardiac surgical patients. Anaesth Intensive Care 1999, 27:13-19.
30. Vaisanen O, Ruokonen E, Parviainen I, Bocek P, Takala J: Ranitidine or dobutamine alone or combined has no effect on gastric intramucosal-arterial PCO(2) difference after cardiac surgery. Intensive Care Med 2000, 26:45-51.
31. Ensinger H, Rantala A, Vogt J, Georgieff M, Takala J: Effect of dobutamine on splanchnic carbohydrate metabolism and amino acid balance after cardiac surgery. Anesthesiology 1999, 91:1587-1595.
32. Romson JL, Leung JM, Bellows WH, Bronstein M, Keith F, Moores W, Flachsbart K, Richter R, Pastor D, Fisher DM: Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology 1999, 91:1318-1328.
33. Hachenberg T, Mollhoff T, Holst D, Hammel D, Brussel T: Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension. J Cardiothorac Vasc Anesth 1997, 11:453-457.
34. Jenkins IR, Dolman J, O'Connor JP, Ansley DM: Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: a prospective, randomized double-blinded trial. Anaesth Intensive Care 1997, 25:245-249.
35. Vroom MB, van Wezel HB, vd Brink RB, vd Lee R, Eijsman L, Visser CA, van Zwieten PA: Effects of dobutamine and enoximone on transmitral and pulmonary venous flow characteristics in patients with left ventricular dysfunction after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1996, 10: 756-763.
36. Parviainen I, Ruokonen E, Takala J: Dobutamine-induced dissociation between changes in splanchnic blood flow and gastric intramucosal pH after cardiac surgery. Br J Anaesth 1995, 74: 277-282.
37. MacGregor DA, Butterworth JF 4th, Zaloga CP, Prielipp RC, James R, Royster RL: Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 1994, 106:835-841.
38. Ruokonen E, Takala J, Kari A: Regional blood flow and oxygen transport in patients with the low cardiac output syndrome after cardiac surgery. Crit Care Med 1993, 21:1304-1311.
39. Dupuis JY, Bondy R, Cattran C, Nathan HJ, Wynands JE: Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. J Cardiothorac Vasc Anesth 1992, 6:542-553.
40. Imai T, Saitoh K, Kani H, Fujita T, Murata K: Combined dose ratios of dopamine and dobutamine and right ventricular performance after cardiac surgery. Chest 1992, 101:1197-1202
41. Boldt J, Kling D, Zickmann B, Dapper F, Hempelmann G: Haemodynamic effects of the phosphodiesterase inhibitor enoximone in comparison with dobutamine in esmolol-treated cardiac surgery patients. Br J Anaesth 1990, 64:611-616.
42. Keogh B, Priddy R, Morgan C, Gillbe C: Comparative study of the effects of enoximone and dobutamine in patients with impaired left ventricular function undergoing cardiac surgery. Cardiology 1990, Suppl 3:58-61.
43. Orellano L, Darwisch M, Dieterich HA, Kollner V: Comparison of dobutamine and enoximone for low output states following cardiac surgery. Int J Cardiol 1990, Suppl 1:S13-S19.
44. Zeplin HE, Dieterich HA, Stegmann T: The effect of enoximone and dobutamine on hemodynamic performance after open-heart surgery. A clinical comparison. J Cardiovasc Surg 1990, 31:574-577.
45. DiSesa VJ, Gold JP, Shemin RJ, Collins JJ Jr, Cohn LH: Comparison of dopamine and dobutamine in patients requiring postoperative circulatory support. Clin Cardiol 1986, 9:253-256.
46. Smith GW, Filek SAL: Dopexamine hydrochloride: a novel dopamine receptor agonist for the acute treatment of low output states. Cardiovasc Drug Rev 1989, 7:141-159.
47. Hurley J, McDonagh P, Cahill M, White M, Luke D, McGovern E, Phelan D: The haemodynamic effect of prophylactic peri-operative dopexamine in coronary artery bypass patients. Eur Heart J 1995, 16:1705-1709.
48. Sherry E, Tooley MA, Bolsin SN, Monk CR, Willcox J: Effect of dopexamine hydrochloride on renal vascular resistance index and haemodynamic responses following coronary artery bypass graft surgery. Eur J Anaesthesiol 1997, 14:184-189.
49. Honkonen EL, Kaukinen L. Kaukinen S, Pehkonen EJ, Laippala P: Dopexamine unloads the impaired right ventricle better than iloprost, a prostacyclin analog, after coronary artery surgery. J Cardiothorac Anesth 1998, 12:647-653.
50. Berendes E, Mollhoff T, Van Aken H, Schmidt C, Erren M, Deng MC, Weyand M, Loick HM: Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth Analg 1997, 84:950-957.
51. Dehne MG, Klein TF, Muhling J, Sablotzki A, Osmer C, Hempelmann G: Impairment of renal function after cardiopulmonary bypass is not influenced by dopexamine. Ren Fail 2001, 23: 217-230.
52. Stephan H, Sonntag H, Henning H, Yoshimine K: Cardiovascular and renal haemodynamic effects of dopexamine: comparison with dopamine. Br J Anaesth 1990, 65:380-387.
53. Sinclair DG, Houldsworth PE, Keogh B, Pepper J, Evans TW: Gastrointestinal permeability following cardiopulmonary bypass: a randomized study comparing the effects of dopamine and dopexamine. Intensive Care Med 1997, 23:510-516.
54. Uusaro A, Ruokonen E, Takala J: Gastric mucosal pH does not reflect changes in splanchnic blood flow after cardiac surgery. Br J Anaesth 1995, 74:149-154.
55. Sharpe DA, Mitchel IM, Kay EA, McGoldrick JP, Munsch CM, Kay PH: Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine. Perfusion 1999, 14: 29-36.
56. Bailey JM, Levy JH, Rogers HG, Szlam F, Hug CC Jr: Pharmacokinetics of amrinone during cardiac surgery. Anesthesiology 1991, 75:961-968.
57. Lewis KP, Appadurai IR, Pierce ET, Halpern EF, Bode RH Jr: Prophylactic amrinone for weaning from cardiopulmonary bypass. Anaesthesia 2000, 55:627-633.
58. Ramsay JG, DeJesus JM, Wynands JE, Ralley FE, O'Connor JP, Robbins GR, Bilodeau J: Amrinone before termination of cardiopulmonary bypass: haemodynamic variables and oxygen utilization in the post postbypass period. Can J Anaesth 1992, 39:342-348.
59. Badner NH, Murkin JM, Shannon NA: An amrinone bolus prior to weaning from cardiopulmonary bypass improves cardiac function in mitral valve surgery patients. J Cardiothorac Vasc Anaesth 1994, 8:410-414.
60. Kikura M, Sato S: The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesth Analg 2002, 94:22-30.
61. Butterworth JF 4th, Royster RL, Prielipp RC, Lawless ST, Wallenhaupt SL: Amrinone in cardiac surgical patients with left-ventricular dysfunction. A prospective, randomized placebo-controlled trial. Chest 1993, 104:1660-1667.
62. Rathmell JP, Prielipp RC, Butterworth JF, Williams E, Villamaria F, Testa L, Viscomi C, Ittleman FP, Baisden CE, Royster RL: A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery. Anesth Analg 1998, 86: 683-690.
63. Zerkowski HR, Gunnicker M, Freund U, Dieterich HA, Dressler HT, Doetsch N, Schieffer M, Hakim-Meibodi K, Lockhart JD, Reidemeister JC: Low output syndrome after heart surgery: is a monotherapy with phosphodiesterase-III inhibitors feasible? A comparitive study of amrinone and enoximone. Thorac Cardiovasc Surg 1992, 40:371-377.
64. Iribe G, Yamada H, Matsunaga A, Yoshimura N: Effects of the phosphodiesterase III inhibitors olprinone, milrinone, and amrinone on hepatosplanchnic oxygen metabolism. Crit Care Med 2000, 28:743-748.
65. Ansell J, Tiarks C, McCue J, Parrilla N, Benotti JR: Amrinone-induced thrombocytopenia. Arch Intern Med 1984, 144:949-952.
66. Gunnicker M, Hess W: Preliminary results with amrinone in perioperative low cardiac output syndrome. Thorac Cardiovasc Surg 1987, 35:219-225.
67. Boldt J, Brosch C, Suttner S, Piper SN, Lehmann A, Werling C: Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intensive Care Med 2002, 28:1462-1469.
68. Boldt J, Knothe C, Zickmann B, Ballesteros M, Russ W, Dapper F, Hempelmann G: The role of enoximone in cardiac surgery. Br J Anaesth 1992, 69:45-50.
69. Boldt J, Kling D, Zickmann B, Dapper F, Hempelmann G: Efficacy of the phosphodiesterase inhibitor enoximone in complicated cardiac surgery. Chest 1990, 98:53-58.
70. Birnbaum DE, Preuner JG, Gieseke R, Trenk D, Jaehnehan E: Enoximone versus dopamine in patients being weaned from cardiopulmonary bypass. Cardiology 1990, Suppl 3: 34-41; discussion: 62-67.
71. Loick HM, Mollhoff T, Berendes E, Hammel D, Van Aken H: Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass. Intensive Care Med 1997, 23:267-275.
72. Boldt J, Knothe C, Zickmann B, Herold C, Dapper E, Hempelmann G: Phosphodiesterase-inhibitors enoximone and piroximone in cardiac surgery: influence on platelet count and function. Intensive Care Med 1992, 18:449-454.
73. Boldt J, Kling D, Dieterich HA, Marck P, Hempelmann G: The new phosphodiesterase inhibitor enoximone in patients following cardiac surgery: pharmacokinetics and influence on parameters of coagulation. Intensive Care Med 1990, 16:54-59.
74. Boldt J, Rothe G, Schindler E, Doll C, Gorlach G, Hempelmann G: Can clonidine, enoximone, and enalaprilat help to protect the myocardium against ischaemia in cardiac surgery? Heart 1996, 76:207-213.
75. De Hert SG, ten Broecke PW, Mertens E, Rodrigus IE, Stockman BA: Effects of phosphodiesterase III inhibition on length-dependent regulation of myocardial function in coronary surgery patients. Br J Anaesth 2002, 88:779-784.
76. Sulek CA, Blas ML, Lobato EB: Milrinone increases middle cerebral artery blood flow velocity after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2002, 16:64-69.
77. Shibata T, Suehiro S, Sasaki Y, Hosono M, Nishi S, Kinoshita H: Slow induction of milrinone after coronary artery bypass grafting. Ann Thorac Cardiovasc Surg 2001, 7:23-27.
78. Yamaura K, Okamoto H, Akiyoshi K, Irita K, Taniyama T, Takahashi S: Effect of low-dose milrinone on gastric intramucosal pH and systemic inflammation after hypothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2001, 15:197-203.
79. Solina A, Papp D, Ginsberg S, Krause T, Grubb W, Scholz P, Pena LL, Cody R: A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 2000, 14: 12-17.
80. Yamada T, Takeda J, Katori N, Tsuzaki K, Ochiai R: Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index. J Cardiothorac Vasc Anesth 2000, 14: 367-373.
81. Hayashida N, Tomoeda H, Oda T, Tayama E, Chihara S, Kawara T, Aoyagi S: Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann Thorac Surg 1999, 68: 1661-1667.
82. Mollhoff T, Loick HM, Van Aken H, Schmidt C, Rolf N, Tjan TD, Asfour B, Berendes E: Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 1999, 90: 72-80.
83. Lobato EB, Florete O Jr, Bingham HL: A single dose of milrinone facilitates separation from cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction. Br J Anaesth 1998, 81:782-184.
84. Kikura M, Levy JH, Michelsen LG, Shanewise JS, Bailey JM, Sadel SM, Szlam F: The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. Anesth Analg 1997, 85:16-22.
85. Doolan LA, Jones EF, Kalman J, Buxton BF, Tonkin AM: A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997, 11:37-41.
86. Prielipp RC, MacGregor DA, Butterworth JF 4th, Meredith JW, Levy JH, Wood KE, Coursin DB: Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. Chest 1996, 109:1291-1301.
87. Butterworth JF 4th, Hines RL, Royster RL, James RL: A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg 1995, 81: 783-792.
88. Kikura M, Lee MK, Safon RA, Bailey JM, Levy JH: The effects of milrinone on platelets in patients undergoing cardiac surgery. Anesth Analg 1995, 81:44-48.
89. Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC Jr: Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology 1994, 81:616-622.
90. Das PA, Skoyles JR, Sherry KM, Peacock JE, Fox PA, Woolfrey SG: Disposition of milrinone in patients after cardiac surgery. Br J Anaesth 1994, 72:426-429.
91. Feneck RO: Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth 1992, 6:563-567.
92. Feneck RO: Intravenous milrinone following cardiac surgery: I. Effects of bolus infusion followed by variable dose maintenance infusion. The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth 1992, 6:554-562.
93. George M, Lehot JJ, Estanove S: Haemodynamic and biological effects of intravenous milrinone in patients with a low cardiac output syndrome following cardiac surgery: multicentre study. Eur J Anaesthesiol 1992, 5:31-34.
94. Wright EM, Sherry KM: Clinical and haemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery. Br J Anaesth 1991, 67:585-590.
95. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002, 360:196-202.
96. Labriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B: Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004, 42:204-211.
97. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, Bailey JM, Akbary A, Kocsis JF, Kaczmarek R, et al.: Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003, 107:996-1002.